Johnson & Johnson files U.S. marketing application for expanded use of Darzalex

|About: Celgene Corporation (CELG)|By:, SA News Editor

Johnson & Johnson (NYSE:JNJ) unit Janssen Pharmaceutical has submitted a supplemental marketing application to the FDA seeking approval for Darzalex (daratumumab), combined with Celgene's (NASDAQ:CELG) Revlimid (lenalidomide) and dexamethasone, for the treatment of patients with newly diagnosed multiple myeloma who are ineligible for autologous stem cell transplant.

The FDA first approved the anti-CD38 monoclonal antibody in November 2015.

Subscribe for full text news in your inbox